Stock listing

Frankfurt:PL4 EchoIQ Limited Aktie

German listing (Frankfurt) of EchoIQ Limited · home listing ASX:EIQ

Follow EchoIQ Limited into a list and get an email when it puts out news.

Home listing price · ASX:EIQ

$0.325 AUD +0.050 (+18.2%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, ASX:EIQ

Past year +38.3% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.260 – $0.340 AUDNov 20, 2026
Volume
13.61M sharesNov 20, 2026
Market cap
$240.8M AUDAt the close on Nov 20, 2026 · price × 740.9M shares outstanding
52-week range
$0.225 – $1.875 AUDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$4.33M AUDMedian day 4.17M shares · 2 days with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026
EchoIQ Limited logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
ASX:EIQ · Home$0.325 AUD+0.050 (+18.2%)13,613,730$0.265$0.340$0.260$0.275Close on Nov 20, 2026
OTC:ECHQF$0.20 USD0.00 (0.0%)—$0.20$0.20$0.20$0.20Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · ASX:EIQ · AUD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.325+0.050+18.2%$0.265$0.340$0.26013,613,730
$0.275-0.200-42.1%$0.470$0.470$0.25510,891,247
$0.475-0.015-3.1%$0.500$0.505$0.4652,533,690
$0.4900.0000.0%$0.490$0.500$0.4801,838,983
$0.490-0.005-1.0%$0.510$0.515$0.4902,098,445
$0.495-0.025-4.8%$0.510$0.525$0.4951,674,590
$0.520-0.015-2.8%$0.530$0.530$0.5101,815,723
$0.535+0.015+2.9%$0.515$0.535$0.5082,367,205
$0.520+0.040+8.3%$0.490$0.525$0.4853,378,548
$0.480-0.020-4.0%$0.495$0.518$0.4753,375,648
$0.500-0.020-3.8%$0.500$0.510$0.4832,682,309
$0.520+0.005+1.0%$0.525$0.540$0.5102,632,540
$0.515+0.030+6.2%$0.480$0.530$0.4804,093,817
$0.485-0.025-4.9%$0.510$0.510$0.4759,549,997
$0.510-0.020-3.8%$0.530$0.530$0.4857,000,657
$0.530-0.020-3.6%$0.550$0.555$0.5203,795,052
$0.550+0.005+0.9%$0.550$0.560$0.5254,811,269
$0.545+0.020+3.8%$0.525$0.565$0.5103,895,076
$0.525+0.010+1.9%$0.515$0.535$0.4655,816,067
$0.515+0.075+17.0%$0.440$0.515$0.4307,132,995
$0.440-0.015-3.3%$0.445$0.450$0.4304,293,008
$0.455+0.040+9.6%$0.415$0.460$0.4056,318,179
$0.415+0.005+1.2%$0.415$0.420$0.4003,387,450
$0.410-0.010-2.4%$0.420$0.420$0.3984,455,531
$0.420-0.010-2.3%$0.425$0.430$0.4152,503,864
$0.4300.0000.0%$0.440$0.445$0.4234,342,952
$0.430-0.045-9.5%$0.465$0.465$0.4308,625,914
$0.475-0.035-6.9%$0.515$0.528$0.46010,458,048
$0.510-0.045-8.1%$0.555$0.575$0.5104,855,767
$0.555+0.025+4.7%$0.580$0.580$0.5454,274,933
$0.530-0.035-6.2%$0.565$0.570$0.5283,756,248
$0.5650.0000.0%$0.560$0.570$0.5503,024,919
$0.565+0.020+3.7%$0.540$0.595$0.5404,166,883
$0.545-0.010-1.8%$0.565$0.570$0.5352,852,297
$0.555-0.025-4.3%$0.580$0.590$0.5552,481,954
$0.580+0.010+1.8%$0.590$0.595$0.5701,922,135
$0.570-0.030-5.0%$0.615$0.615$0.5703,537,523
$0.600+0.055+10.1%$0.570$0.620$0.5505,455,239
$0.545+0.005+0.9%$0.550$0.570$0.5405,741,969
$0.540-0.050-8.5%$0.585$0.590$0.5406,998,875
$0.590-0.080-11.9%$0.655$0.660$0.58011,481,317
$0.670+0.030+4.7%$0.650$0.695$0.6508,573,846
$0.640-0.015-2.3%$0.650$0.675$0.6303,732,788
$0.655-0.055-7.7%$0.710$0.715$0.6209,764,216
$0.710-0.065-8.4%$0.740$0.848$0.69023,978,030
$0.775+0.185+31.4%$0.610$0.785$0.59545,753,628
$0.590+0.075+14.6%$0.520$0.610$0.52013,230,652
$0.515-0.025-4.6%$0.545$0.568$0.51511,403,339
$0.540+0.055+11.3%$0.470$0.540$0.47011,085,381
$0.485-0.030-5.8%$0.520$0.530$0.4807,993,387
$0.515-0.055-9.6%$0.550$0.560$0.48017,399,526
$0.570-0.070-10.9%$0.600$0.645$0.54015,555,802
$0.640-0.640-50.0%$0.480$0.730$0.47053,407,765
$1.2800.0000.0%$1.280$1.280$1.2800
$1.2800.0000.0%$1.280$1.280$1.2800
$1.280+0.055+4.5%$1.260$1.315$1.2054,613,105
$1.225-0.060-4.7%$1.300$1.320$1.2154,478,839
$1.285-0.030-2.3%$1.290$1.335$1.2702,189,691
$1.315-0.100-7.1%$1.400$1.400$1.3103,853,858
$1.415+0.020+1.4%$1.380$1.450$1.3453,886,080
$1.395-0.115-7.6%$1.510$1.560$1.3656,053,889
$1.510-0.030-1.9%$1.530$1.590$1.4951,881,433
$1.540-0.020-1.3%$1.565$1.588$1.5301,977,773
$1.560+0.070+4.7%$1.490$1.560$1.4451,515,953
$1.490-0.055-3.6%$1.545$1.565$1.4802,024,054
$1.545-0.015-1.0%$1.575$1.595$1.5151,766,848
$1.560+0.060+4.0%$1.525$1.568$1.4902,236,235

Splits

2 splits since 2015 · ASX:EIQ · every price before a split is adjusted for it

DayRatioWhat
1-for-10Consolidation
1.0573-for-1Split
Ticker
Frankfurt:PL4
Asset type
Stock
Sector
Health care
Industry
Health care services
Exchange
Frankfurt
Currency
EUR

What changed lately

Latest news

Cleansing Notice

Nov 19, 2026

Closed $0.325 (+18.2%) on Nov 20, 2026

Application for quotation of securities - EIQ

Nov 19, 2026

Closed $0.325 (+18.2%) on Nov 20, 2026

EchoSolv HF regulatory update

Nov 18, 2026

Closed $0.275 (-42.1%) on Nov 19, 2026

Trading Halt

Nov 18, 2026

Closed $0.275 (-42.1%) on Nov 19, 2026

Pause in Trading

Nov 18, 2026

Closed $0.275 (-42.1%) on Nov 19, 2026

All EchoIQ Limited news

EchoIQ Limited on 6ix

Sector
Health care
Industry
Health care services
News releases
55 in the last 12 months · 245 in all · newest Nov 20, 2026 · oldest 2016
Decks
12 decks · latest Nov 17, 2026

Where EchoIQ Limited is listed

ListingExchangeCountryCurrency
ASX:EIQ · Home listingASXAustraliaAUD
gettex:PL4gettexGermanyEUR
OTC:ECHQFOTCUnited StatesUSD
Tradegate:PL4TradegateGermanyEUR
LS Exchange:A3C84ALS ExchangeGermanyEUR
Lang & Schwarz:A3C84ALang & SchwarzGermanyEUR
Hamburg:PL4HamburgGermanyEUR
Frankfurt:PL4 · This pageFrankfurtGermanyEUR
Munich:PL4MunichGermanyEUR
Stuttgart:PL4StuttgartGermanyEUR

Valuation

EV/sales 2,523× against a median of 0.9×: the highest of 11 Health care services companies shown. Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026

Enterprise value
$232.1M AUD
P/E
Loss
EV/sales
2,523×
EV/EBITDA
Negative EBITDA
Price/book
20.7×
Gross margin
Revenue too small
Operating margin
Revenue too small
Net margin
Revenue too small
Debt to equity
0.0×
Beta
No index for this market yet

Health care services: the 10 companies nearest in size, of 419 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
EchoIQ Limited · ASX:EIQUS$159.4MUS$153.6Mn/a2,523×n/a20.7×n/a0.0×n/a
PT Prodia Widyahusada Tbk · IDX:PRDAUS$166.2MUS$128.9M13.9×1.0×4.7×1.3×9.0%0.0×n/a
American Well Corporation · NYSE:AMWLUS$165.1M−US$13.64Mn/a−0.1×n/a0.8×−27.0%0.0×0.96
PT Nitrasanata Dharma Tbk · IDX:JECXUS$163.0MUS$148.8M41.1×2.9×13.9×3.0×7.8%0.0×n/a
Rici Healthcare Holdings Ltd. · HKEX:1526US$162.9MUS$282.0M3.5×0.7×1.7×0.7×11.0%1.1×n/a
Carasent AB · OMXSTO:CARAUS$161.2MUS$159.0M41.7×4.2×18.9×2.0×10.1%0.0×n/a
Srivichaivejvivat Public Co. Ltd. · SET:VIHUS$158.4MUS$118.6M12.0×1.3×5.5×1.4×14.3%0.0×n/a
ILEX Medical Ltd. · TASE:ILXUS$157.2MUS$107.2M13.6×0.4×4.0×0.8×4.4%0.1×n/a
Profarma Distribuidora de Produtos Farmaceuticos SA · BMFBOVESPA:PFRM3US$154.2MUS$392.9M5.9×0.2×3.7×0.6×1.2%1.3×n/a
Rajthanee Hospital Public Company Limited · SET:RJHUS$153.8MUS$169.2M14.0×2.0×9.9×2.3×12.7%0.3×n/a
Bastide Le Confort Medical SA · EURONEXT:BLCUS$153.5MUS$428.9M2.4×0.8×3.7×1.1×12.0%2.3×n/a
Median of the othersUS$159.8MUS$153.9M13.6×0.9×4.7×1.2×9.6%0.1×0.96

Forecasts

Analysts' consensus from EODHD, read Nov 15, 2026. Not 6ix's view and not investment advice.

Price target
0.91 AUD · Analysts' mean
EPS, year to Jun 2027
-0.020 · 4 analysts
Revenue, year to Jun 2027
2.04M · 2 analysts

Team and board

OfficerRole
Dustin HainesChief Executive Officer
Matthew DoddsChief Financial Officer
Nick LubbersUS President and General Manager
Dane BrescacinSVP Regulatory Affairs
Patrick O’SheaHead of Strategy & Operations
Sam DribinChief Technology Officer

Events

QuarterResultsShare move
Q2 2025Aug 29, 2025 · Before open−2.3%
Q4 2024Feb 27, 2025−6.9%
Q4 2022Feb 28, 2023 · After close0.0%
Q2 2022Sep 30, 2022 · After close0.0%
Q4 2021Feb 28, 2022+3.7%
Q2 2021Aug 31, 2021+12.5%
Q4 2020Feb 25, 2021−1.9%

Open Events

Decks

DeckKindSlidesDate
Bell Potter Healthcare Conference 2026Conference22 slidesNov 17, 2026
Conference Presentation (November 2025)Conference20 slidesNovember 2025
Investor Presentation (March 2025)Investor deck29 slidesMar 7, 2025
Investor Presentation (May 2024)Investor deck21 slidesMay 23, 2024
Investor Presentation (October 2023)Investor deck23 slidesOct 16, 2023
Investor Presentation (May 2023)Investor deck17 slidesMay 11, 2023
Investor Presentation (April 2022)Investor deck17 slidesApr 28, 2022
Investor Presentation (February 2022)Investor deck20 slidesFeb 4, 2022
ShareCafe Small Cap Hidden Gems Webinar 2021Conference13 slidesOct 29, 2021
Investor Presentation (September 2021)Investor deck20 slidesSep 7, 2021
All 12 decks
DeckKindSlidesDate
Houston We Have — Shareholder Meeting (November 2020)Shareholder meeting14 slidesNov 27, 2020
Houston We Have — Investor Presentation (May 2020)Investor deck14 slidesMay 28, 2020

Open Decks

Financials

Annual, in AUD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue92.0K101.4K44.5K107.3K251.1K442.0K679.9K824.5K14.6K146.3K
Cost of revenue16.4M3.24M2.92M7.12M3.44M2.19M1.78M568.9K635.4K753.1K
Gross profit-16.3M-3.14M-2.88M-7.01M-3.19M-1.75M-1.10M255.6K-620.8K-606.9K
Selling, general and administrative13.7M9.59M4.23M5.34M4.24M2.40M1.70M580.6K1.62M968.8K
Operating income-19.8M-13.0M-5.92M-6.96M-6.53M-3.35M-2.85M-338.3K-2.43M-1.67M
Depreciation and amortization549.0K577.2K603.7K607.3K640.2K270.1K129.9K871.47K2.66K
EBITDA-19.3M-12.4M-5.32M-6.35M-5.89M-3.08M-2.72M-338.2K-2.43M-1.67M
Interest expense1.63K1.63K16.2K104.9K2.51K11.3K
Income before tax-18.6M-13.3M-5.41M-8.27M-6.49M-3.41M-2.68M-474.9K-2.00M-14.3M
Income tax43-498.6K-417.9K-122-171.8K
Net income-18.6M-13.3M-5.41M-8.27M-5.99M-2.99M-2.68M-474.9K-2.00M-14.3M
Earnings per share, basic-0.03-0.02-0.01-0.02-0.02-0.01-0.01-0.01-0.06-0.44

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents8.71M6.62M2.12M3.28M2.41M3.81M3.48M714.0K473.9K362.3K
Short-term investments11.5M21
Receivables148.0K214.7K100.0K636.5K270.3K350.3K85.4K157.2K313.4K514.1K
Inventory-100.0K1-89401-313.4K-514.1K
Current assets9.64M18.6M2.45M3.98M3.22M4.28M3.56M872.0K787.2K919.0K
Property, plant and equipment35.3K14.4K34.1K40.1K33.1K74.8K1502407.00K
Goodwill139.2K139.2K139.2K139.2K
Total assets13.9M23.4M8.26M10.4M10.2M10.9M4.15M876.1K789.3K940.4K
Accounts payable763.0K224.3K375.4K109.8K239.8K259.0K50.0K108.0K64.4K162.2K
Current liabilities2.25M615.4K1.49M3.00M2.21M1.10M1.01M1.33M930.2K548.9K
Total debt43.8K43.8K782.7K317.7K
Total liabilities2.25M615.4K1.49M3.00M2.21M1.10M1.03M1.34M936.7K599.2K
Shareholders' equity11.6M22.8M6.77M7.38M8.02M9.84M3.12M-464.7K-147.4K341.2K
Shares outstanding652.7M585.7M497.6M448.0M392.8M276.9M225.3M70.4M35.9M32.2M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-10.6M-6.51M-3.92M-4.94M-2.58M-1.43M-1.10M-202.2K-1.66M-2.29M
Capital spending-53.0K-35.8K-4-339.7K-367.3K-1.00M-88.5K-88.5K-3.03K-787
Free cash flow-10.6M-6.54M-3.92M-5.28M-2.95M-2.43M-1.19M-202.2K-1.66M-2.29M
Cash from investing11.5M-11.6M-59.8K-367.3K-1.00M-342.8K0407.0K49.2K
Cash from financing1.22M22.6M2.77M5.88M1.55M2.77M4.21M442.4K1.37M-763.2K
Dividends paid-2.61M-3.80M-407.7K
Share buybacks-187.0K-168.0K-153.8K-407.7K-407.7K1.05M1.37K
Change in cash2.09M4.50M-1.16M869.5K-1.41M334.9K2.76M240.2K111.6K344.8K

Open Financials

Filings

FilingDateTypeFiled with
Cleansing NoticeNov 19, 2026FinancingASX
Application for quotation of securities - EIQNov 19, 2026FinancingASX
EchoSolv HF regulatory updateNov 18, 2026Legal or regulatory actionASX
Trading HaltNov 18, 2026Trading halt or suspensionASX
Pause in TradingNov 18, 2026Trading halt or suspensionASX
Bell Potter Healthcare Conference PresentationNov 16, 2026Other filingsASX
Dr Vasum Peiris Appointed as Chief Medical OfficerNov 15, 2026Management or board changeASX
Notification regarding unquoted securities - EIQNov 4, 2026Other filingsASX
Quarterly Activities Report & Appendix 4C Cashflow ReportOct 25, 2026Quarterly reportASX
Notice of Annual General Meeting/Proxy FormOct 23, 2026Meeting noticeASX
Show 200 filings
FilingDateTypeFiled with
Notification of cessation of securities - EIQOct 22, 2026FinancingASX
EchoSolv HF FDA 510(k) updateOct 11, 2026Operations updateASX
Date of AGM and Closing Date for Director NominationsOct 6, 2026Meeting noticeASX
EchoSolv HF FDA application updateSep 16, 2026Operations updateASX
Notification regarding unquoted securities - EIQSep 14, 2026Other filingsASX
Cleansing NoticeSep 10, 2026FinancingASX
Application for quotation of securities - EIQSep 10, 2026FinancingASX
Investor WebinarSep 8, 2026Other filingsASX
EchoSolv HF FDA Application UpdateSep 8, 2026Operations updateASX
Trading HaltSep 6, 2026Trading halt or suspensionASX
Pause in TradingSep 6, 2026Trading halt or suspensionASX
Notification of cessation of securities - EIQSep 4, 2026FinancingASX
S&P DJI Announces September 2026 Quarterly RebalanceSep 4, 2026Other filingsASX
Proposed issue of securities - EIQSep 1, 2026FinancingASX
Initial Director's Interest Notice - Scott WilkinSep 1, 2026Ownership change noticeASX
Global healthcare investment leader appointed to BoardAug 31, 2026Management or board changeASX
Appendix 4G and Corporate Governance StatementAug 27, 2026Other filingsASX
Annual Report to ShareholdersAug 27, 2026Annual reportASX
Preliminary Final ReportAug 27, 2026ResultsASX
Cleansing NoticeAug 21, 2026FinancingASX
Application for quotation of securities - EIQAug 21, 2026FinancingASX
Convertible note executed with Pro MedicusAug 16, 2026FinancingASX
Cleansing NoticeAug 7, 2026FinancingASX
Application for quotation of securities - EIQAug 7, 2026FinancingASX
Investor WebinarJul 27, 2026Other filingsASX
Quarterly Activities Report & Appendix 4C Cashflow ReportJul 26, 2026Quarterly reportASX
Exclusive Imaging Dataset Strengthens AI Competitive MoatJul 1, 2026Operations updateASX
Echo IQ Raises A$110m via Institutional PlacementJun 30, 2026FinancingASX
Binding HOA secured with Pro Medicus LimitedJun 24, 2026Other filingsASX
Research collaboration secured with Mayo ClinicJun 11, 2026Operations updateASX
$762k R&D Tax Incentive ReceivedMay 25, 2026FinancingASX
QuarterlyActivities Report and Appendix 4C Cash Flow ReportApr 29, 2026Quarterly reportASX
EchoSolv AS deployed into Mount Sinai Health SystemApr 27, 2026Operations updateASX
Agreement with Mayo Clinic for EchoSolv HFMar 23, 2026Material contractASX
Update - S&P DJI March 2026 Rebalance of the All OrdinariesMar 10, 2026Other filingsASX
S&P DJI Announces March 2026 Quarterly RebalanceMar 6, 2026Other filingsASX
Appendix 4D 31 December 2025Feb 26, 2026Interim reportASX
Quarterly Activities Report and Appendix 4C Cash Flow ReportJan 23, 2026Quarterly reportASX
Response to ASX Price QueryJan 22, 2026Explanation requestASX
Formal lodgement of FDA submission for EchoSolv HFDec 14, 2025Operations updateASX
Exceptional Results from Validation Study for EchoSolv HFNov 23, 2025ResultsASX
Quarterly Activities and Appendix 4C Cash Flow ReportOct 30, 2025Quarterly reportASX
Category III CPT code application updateOct 6, 2025Operations updateASX
Trading HaltOct 5, 2025Trading halt or suspensionASX
Pause in TradingOct 5, 2025Trading halt or suspensionASX
Strong Operational MomentumOct 2, 2025Operations updateASX
Update on Category III CPT Code ApplicationSep 19, 2025Operations updateASX
Preliminary Final ReportAug 29, 2025ResultsASX
Quarterly Activities & Appendix 4C Cashflow ReportsJul 24, 2025Quarterly reportASX
Reseller Agreement Secured with SARC MedIQJul 10, 2025Operations updateASX
Mayo Clinic Validation Study UnderwayJul 1, 2025Operations updateASX
Echo IQ raises $17.3m via institutional placementMay 7, 2025FinancingASX
Listing on the OTCQB MarketApr 16, 2025Other filingsASX
Echosolv Collaboration Agreement with Mayo Clinic PlatformApr 2, 2025Operations updateASX
Expansion Across 36 US Hospitals and Cardiology PracticesMar 30, 2025Operations updateASX
Investor Webinar PresentationMar 6, 2025Other filingsASX
Strong Progress in First Two Months of CY25 AchievedMar 4, 2025Other filingsASX
Appendix 4D 31 December 2024Feb 27, 2025Interim reportASX
$1.26M R&D TAX INCENTIVE RECEIVEDFeb 12, 2025Other filingsASX
Response to ASX Query LetterJan 31, 2025Explanation requestASX
PRE-SUBMISSION MEETING WITH US FDA FOR HEART FAILUREDec 23, 2024Operations updateASX
The First Step in EIQs US Market Commercialisation StrategyDec 8, 2024Operations updateASX
S&P DJI Announces December 2024 Quarterly RebalanceDec 6, 2024Other filingsASX
EIQ signs integration agreement with Flagship US HospitalNov 17, 2024Other filingsASX
US Based CEO Appointed to Execute Commercialisation StrategyOct 8, 2024Management or board changeASX
Major Milestone Achieved with FDA Clearance for EchoSolv ASOct 7, 2024Other filingsASX
Echo IQ Raises $7.1 millionSep 6, 2024FinancingASX
Groundbreaking study results for Heart Failure AI solutionSep 3, 2024ResultsASX
Strategic Integration Partnership Agreement with ScImage IncJul 4, 2024Operations updateASX
Validation of EIQ AI at Leading Scientific ConferenceJun 5, 2024Operations updateASX
Investor PresentationMay 22, 2024Other filingsASX
Echo IQ Commences New Heart Failure Clinical Study Using AIMay 20, 2024Operations updateASX
US FDA Application LodgedMay 6, 2024Operations updateASX
Quarterly ReportApr 30, 2024Quarterly reportASX
Appendix 4C Cash Flow ReportApr 30, 2024Quarterly reportASX
Management UpdateApr 1, 2024Management or board changeASX
Completion of US Reader StudyMar 27, 2024Operations updateASX
Receipt of Research & Development Tax IncentiveMar 7, 2024Other filingsASX
Appendix 4D 31 December 2023Feb 28, 2024Interim reportASX
RSH: Cardiovascular AI platform integrated into RPM programJan 24, 2024Other filingsASX
EIQ Licenses Software to Respiri - Remote Patient Mon.Jan 24, 2024Other filingsASX
EIQ Appoints Kimber Rothwell as CEOJan 15, 2024Management or board changeASX
Business Progress UpdateDec 13, 2023Operations updateASX
Ord Minnett Healthcare ForumOct 29, 2023Operations updateASX
Quarterly Activities ReportOct 24, 2023Quarterly reportASX
EIQ Investor Presentation updatedOct 15, 2023Other filingsASX
Paid Pilot with Australias Largest Cardiology ProviderAug 28, 2023Other filingsASX
Significant Expansion of EchoSolv Solutions SuiteAug 20, 2023Other filingsASX
Echo IQ Advances Global Regulatory Compliance StrategyAug 1, 2023Other filingsASX
LAUNCH OF NEW ECHOSOLV SOLUTION FOR MITRAL REGURGITATIONJul 18, 2023Other filingsASX
ECHO IQ SECURES MAIDEN AUSTRALIAN HOSPITAL SALE OF ECHOSOLVJun 21, 2023Other filingsASX
US Cardiovascular Facilities Access EchoSolv via StudycastJun 12, 2023Other filingsASX
Echo IQ Delivers on CommercialisationMay 8, 2023Other filingsASX
HYD: Hydrix signs agreement to sell EIQ's EchoSolv platformMay 1, 2023Other filingsASX
Echo IQ Expands Commercial FootprintMay 1, 2023Other filingsASX
Quarterly Activities/Appendix 4C Cash Flow ReportApr 28, 2023Quarterly reportASX
Flagship Clinical Trial Results At St Vincent HospitalsApr 19, 2023Other filingsASX
Appendix 4D 31 December 2022Feb 28, 2023Interim reportASX
Amendment to Quarterly ReportFeb 1, 2023Quarterly reportASX
Quarterly Activities/Appendix 4C Cash Flow Report - DecJan 24, 2023Quarterly reportASX
Positive Interim Results From Clinical Trial at St VincentsDec 14, 2022Interim reportASX
Echo IQ Launches EchoSolv for Immediate DistributionDec 6, 2022Other filingsASX
Echo IQ Announces Positive Results From US Clinical StudyNov 30, 2022Other filingsASX
Amendment to Appendix 4CNov 11, 2022Quarterly reportASX
Quarterly Activities/Appendix 4C Cash Flow Report - SeptOct 28, 2022Quarterly reportASX
Reinstatement to Official QuotationOct 12, 2022Trading halt or suspensionASX
Echo IQ Selected for HeartX Accelerator & FundingOct 11, 2022Other filingsASX
Suspension from Official QuotationOct 6, 2022Trading halt or suspensionASX
New Research Presented at Leading Cardiology ConferenceAug 30, 2022Other filingsASX
New Clinical Study with World-Leading US Teaching HospitalJul 26, 2022Other filingsASX
Updated Appendix 4C Quarterly Cash Flow ReportJul 19, 2022Quarterly reportASX
Quarterly Activities/Appendix 4C Cash Flow Report - JuneJul 18, 2022Quarterly reportASX
Presentation of Research Findings Behind Echo IQ AlgorithmJul 6, 2022Other filingsASX
Sale of Prometheus Information Pty. LimitedMay 8, 2022Other filingsASX
Formation of Scientific Advisory BoardApr 25, 2022Other filingsASX
Quarterly Activities/Appendix 4C Cash Flow Report - MarchApr 12, 2022Quarterly reportASX
Appendix 4D 31 December 2021Feb 28, 2022Interim reportASX
STRATEGIC TRANSFORMATION AND NEW AGREEMENTOct 19, 2021Other filingsASX
Vesting of Performance SharesOct 1, 2021Other filingsASX
ECHOiQ Strategic PartnershipSep 21, 2021Other filingsASX
ECHOiQ Investor PresentationSep 6, 2021Other filingsASX
ECHOiQ Clinical TrialSep 5, 2021Other filingsASX
ECHOiQ Six Weeks of Rapid ProgressJul 14, 2021Other filingsASX
Positive Due Diligence Completed for ECHO IQ AcquisitionMay 19, 2021Acquisition or disposalASX
Quarterly Activities and Cash Flow Report - March 21Apr 29, 2021Quarterly reportASX
HWH Two New Innovation Projects in the UKApr 28, 2021Other filingsASX
HWH Acquires Specialist AI Company ECHO IQMar 30, 2021Acquisition or disposalASX
Appendix 3BMar 30, 2021FinancingASX
H1 2021 AnnouncementFeb 25, 2021Other filingsASX
Appendix 4D 31 December 2020Feb 25, 2021Interim reportASX
Houston We Have and Wipro Form a Strategic AllianceFeb 9, 2021Other filingsASX
Quarterly Activities and Cash Flow Report - December 2020Jan 28, 2021Quarterly reportASX
New Client Engagement and Contract GrowthDec 16, 2020Other filingsASX
Quarterly Activities and Cash Flow Reports - September 2020Oct 25, 2020Quarterly reportASX
Appendix 4E & Unaudited Preliminary Financial StatementsAug 31, 2020ResultsASX
Quarterly Activities and Cash Flow Reports - June 2020Jul 31, 2020Quarterly reportASX
HWH Confirms $400,000 in Annual Contract RenewalsMay 19, 2020Other filingsASX
New Contract Wins Validate Growth StrategyMay 5, 2020Material contractASX
Quarterly Activities Report and Appendix 4C - March 2020Apr 30, 2020Quarterly reportASX
Half Year Results AnnouncementFeb 28, 2020Interim reportASX
Appendix 4D and FY20 Interim Financial ReportFeb 28, 2020Interim reportASX
Cleansing ProspectusFeb 2, 2020Offer documentASX
Quarterly Activities Report and Appendix 4C - December 2019Jan 31, 2020Quarterly reportASX
Veriluma Appendix 4C - September 2019 QuarterOct 31, 2019Quarterly reportASX
Veriluma Quarterly Activities Report - September 2019Oct 30, 2019Quarterly reportASX
Department of Defence Appoints VRI for Additional ServicesOct 7, 2019Other filingsASX
Strategic Acquisition of PrometheusOct 6, 2019Acquisition or disposalASX
Veriluma Closes Over-Subscribed Capital RaisingSep 3, 2019FinancingASX
Supplementary ProspectusSep 1, 2019Offer documentASX
Appendix 4E - Preliminary Final Report (30 June 2019)Aug 30, 2019ResultsASX
ProspectusJul 28, 2019Offer documentASX
Appendix 4C - June 2019 Quarter (Replacement)Jul 26, 2019Quarterly reportASX
Appendix 4C - June 2019 QuarterJul 24, 2019Quarterly reportASX
Notice of Annual General Meeting and Proxy FormJul 8, 2019Meeting noticeASX
Receipt of FundsJul 4, 2019Other filingsASX
June 18 Quarterly Activities Report and App 4CMay 17, 2019Quarterly reportASX
Mar 18 Quarterly Activities Report and App 4CMay 16, 2019Quarterly reportASX
Dec 17 Quarterly Activities Report and App 4CMay 16, 2019Quarterly reportASX
HYE Dec 18 App 4D and Interim Financial ReportMay 16, 2019Interim reportASX
FYE June 2018 App 4E and Annual ReportMay 16, 2019Annual reportASX
HYE Dec 17 App 4D and Interim Financial ReportMay 16, 2019Interim reportASX
March 2019 Quarterly Activities and Appendix 4CApr 30, 2019Quarterly reportASX
Veriluma and MITN PartnershipFeb 24, 2019Other filingsASX
VRI to commence Department of Defence ContractFeb 21, 2019Other filingsASX
December 2018 Quarterly Activities and Appendix 4CJan 31, 2019Quarterly reportASX
September 2018 Quarterly Activities and Appendix 4CJan 31, 2019Quarterly reportASX
Suspension from Official Quotation - Annual Listing FeesAug 22, 2018Trading halt or suspensionASX
Veriluma to acquire Concept Safety SystemsSep 20, 2017Acquisition or disposalASX
Appendix 4EAug 31, 2017ResultsASX
Quarterly Activities Report and Appendix 4CJul 28, 2017Quarterly reportASX
Veriluma Completes Sale of Mining AssetJul 24, 2017Other filingsASX
VRI Partners with US-based Diamond Capture AssociatesApr 26, 2017Other filingsASX
VRI Boosts Cash Balance with Sale of Mining AssetsApr 20, 2017Other filingsASX
Appendix 4DFeb 28, 2017Interim reportASX
Leading Law Firm to Trial VRIs Prescriptive AnalyticsFeb 13, 2017Other filingsASX
Update on Contract with Departmenrt of DefenceDec 22, 2016Other filingsASX
VRI Secures Contract with Australian Department of DefenceDec 18, 2016Other filingsASX
Appendix 4C - quarterlyOct 30, 2016Quarterly reportASX
Reinstatement to Official Quotation (27/09/2016)Oct 6, 2016Trading halt or suspensionASX
Suspenion from Official QuotationJul 12, 2016Other filingsASX
Transaction UpdateMay 10, 2016Other filingsASX
Quarterly Activities Report and Quarterly Cashflow ReportApr 28, 2016Quarterly reportASX
Veriluma Secures Commercial Agreement with RPMGApr 20, 2016Other filingsASX
Veriluma Enters Strategic Partnership with Global BusinessApr 3, 2016Other filingsASX
Parmelia Closes Over-Subscribed $1.1M Capital RaisingMar 30, 2016FinancingASX
MOA to Acquire Boston Gold Project in PhilippinesMar 30, 2016Acquisition or disposalASX
Results of Phase 1 Scout Drilling at Darvii Naruu, MongoliaMar 30, 2016Operations updateASX
PlacementMar 30, 2016FinancingASX
Survey commences at Darvii Naruu Cu-Au project, MongoliaMar 30, 2016Other filingsASX
Agreement signed to acquire Mongolian Copper Gold projectMar 30, 2016Acquisition or disposalASX

This page holds 200 of 236 filings. Open Filings

Open Filings

Cap table

Built by 6ix from EchoIQ Limited’s releases

Common shares
740,874,779
Fully diluted
740,874,779

Fully diluted

LineShares
Common shares740,874,779

Share count over time

CountShares
Nov 22, 2026740,874,779

Open Cap table

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Dane BrescacinSVP Regulatory Affairs · Since at least Nov 16, 2026
Dustin HainesChief Executive Officer · Since at least Nov 24, 2025
Matthew DoddsChief Financial Officer · Since at least Jun 24, 2026
Nick LubbersUS President and General Manager · Since at least Apr 30, 2026
Patrick O’SheaHead of Strategy & Operations · Since at least Nov 16, 2026
Sam DribinChief Technology Officer · Since at least Nov 16, 2026

Open People

Log in to ask 6ix AI your own questions about EchoIQ Limited.